SCHEMBL6822009

SCHEMBL6822009

CC(C)n1nc(-c2c(-c3ccccc3)nn3ccc(O)cc23)ccc1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 1/20 0.45
IGF1R P08069 2/20 0.39
MAPK1 P28482 4/20 0.37
TP53 P04637 2/20 0.36
POLB P06746 2/20 0.36
PDE1A P54750 1/20 0.35
PDE1B Q01064 1/20 0.35
PDE1C Q14123 1/20 0.35
KMT2A Q03164 1/20 0.34
MAPK3 P27361 1/20 0.34
MAPK14 Q16539 1/20 0.34
CMKLR1 Q99788 1/20 0.34
MAPT P10636 1/20 0.33
THRB P10828 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
BMPR1B O00238 1/20 0.33
BMPR1A P36894 1/20 0.33
TGFBR1 P36897 1/20 0.33
ACVRL1 P37023 1/20 0.33
ACVR1 Q04771 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6818544 0.87 ADORA1 (0.46) ADORA1IGF1RMAPK1TP53POLB
SCHEMBL6822067 0.87 ADORA1 (0.43) ADORA1IGF1RMAPK1TP53POLB
SCHEMBL7039587 0.85 ADORA1 (0.57) ADORA1IGF1RMAPK1MAPK3MAPK14
SCHEMBL6821959 0.85 ADORA1 (0.42) ADORA1IGF1RMAPK1PDE1APDE1B
SCHEMBL6822360 0.85 ADORA1 (0.44) ADORA1IGF1RMAPK1TP53POLB
SCHEMBL6818390 0.85 ADORA1 (0.44) ADORA1IGF1RMAPK1TP53POLB
SCHEMBL6825134 0.84 ADORA1 (0.41) ADORA1IGF1RMAPK1TP53POLB
SCHEMBL6822257 0.84 ADORA1 (0.43) ADORA1IGF1RMAPK1TP53POLB
SCHEMBL6822033 0.84 ADORA1 (0.41) ADORA1IGF1RMAPK1TP53POLB
SCHEMBL6818470 0.84 ADORA1 (0.41) ADORA1IGF1RMAPK1MAPK3MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110763-A1 Pyrazolopyridine compound and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 US disclosed
EP-1313733-A1 PYRAZOLOPYRIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-05-28 EP disclosed
WO-2002018382-A1 PYRAZOLOPYRIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110763-A1 Pyrazolopyridine compound and pharmaceutical use thereof ADRB1, ADRA1D, ADRB3 ADORA1 22/4885IGF1R 4150/4885MAPK1 1491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.